Enterprise Europe Network

Russian producer of a drug for the emergency prevention of tick-borne encephalitis is looking for foreign partners to conclude a license agreement

Country of origin:
Country: 
RUSSIA
Opportunity:
External Id: 
TORU20210721001
Published
21/07/2021
Last update
28/07/2021
Expiration date
29/07/2022

Keywords

Partner keyword: 
Medical Research
Pharmaceutical Products / Drugs
MEDICAL/HEALTH RELATED
Pharmaceuticals/fine chemicals
Manufacture of pharmaceutical preparations
EXPRESS YOUR INTEREST

Summary

Summary: 
A Russian company from the Tomsk region has developed a drug against tick-borne encephalitis. This drug can be used both before and after sucking the tick. The drug has an antiviral, membrane-stabilizing and anti-inflammatory effect. The Russian company is interested in finding partners from foreign countries to register and commercialize this drug based on a licensing agreement.

Description

Description: 

The Russian company from Tomsk was founded in 2002. Now the company is a leader in the development of highly effective drugs for health.
Tick-borne encephalitis is a dangerous viral disease carried by ticks. The tick-borne encephalitis virus begins to affect the cells of the brain and spinal cord within 24 hours after the tick is sucked. Untimely prevention of the disease and the development of tick-borne encephalitis can cause irreparable harm to human health and even lead to his death.
At the moment, different countries are developing various preventive measures against encephalitis ticks. These are special chemical aerosols, sprays and bracelets that can scare away ticks. These funds have a strong chemical composition that can cause a severe allergic reaction. In addition to these funds, a vaccine against encephalitic tick is being developed. However, for many patients who have chronic diseases, respiratory diseases, cardiovascular diseases, vaccination is contraindicated.
The Russian company has developed a highly effective drug against tick-borne encephalitis. This is the only tablet drug with a direct indication of prevention and emergency care for the absorption of tick-borne encephalitis. The drug does not cause allergic reactions and can be used in patients with chronic diseases. The drug can be used both before as a preventive measure, and after sucking the tick.
The drug has the following effect:
- antiviral effect-suppresses the reproduction of the virus,
- membrane-stabilizing effect-prevents the virus from entering the cell by blocking the fusion of the virus with the cell membrane,
- anti-inflammatory effect-reduces the inflammatory process,
- immunostimulating effect activates the immune system naturally, stimulating cellular and humoral immunity to fight the virus.
To achieve optimal results, the drug should be used strictly following all the recommendations set out in the instructions. The Russian company provides all the necessary instructions, as well as a special registration number and supporting documents.
The Russian company is looking for foreign partners from different countries, especially from Southeast Asia (Vietnam, Thailand, Japan, Singapore, etc.), where tick-borne encephalitis is more common to conclude a license agreement. In accordance with the license agreement, the Russian company plans to register its drug in other countries. The potential partner will have to help the Russian company in obtaining the necessary documentation and registration of the drug. Also, a potential partner will receive a special license to distribute the drug on its foreign market. The licensee must provide a service in passing the examination of the drug in specialized bodies to obtain a permissive document.

Advantages & innovations

Cooperation plus value: 
The data of monitoring the epidemiological situation following the results of the epidemiological seasons of tick-borne encephalitis showed: 1) when using the drug, the percentage of patients with tick-borne encephalitis is 5 times lower, compared with human Immunoglobulin against tick-borne encephalitis, with a confidence probability of 95 %. 2) when using the drug, the percentage of patients with tick-borne encephalitis is 15 times lower than among patients who did not receive prevention. The Russian drug has already protected more than 2448282 people.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
Type: SMEs, large companies, pharmacological companies, companies from the field of medicine. Role: In accordance with the license agreement, the potential partner will have to help the Russian company in obtaining the necessary certification and documentation on the foreign market, as well as register the drug. A potential licensee will be able to obtain a license to distribute the drug on its market. Thanks to this, the partner will be able to sell products to various medical institutions.